IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1498-119 C#

c'd PCT/PTO 2

SQUIRRELL et al.

Serial No. 09/763,82

Filed: February 27

Title:

Group Art Unit: 1652 Examiner:

Date: April 29, 2002

NOVEL ENZYME

Fees are attached as calculated below:

Assistant Commissioner for Patents Washington, DC 20231

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Total effective claims after amendment 0 minus highest number previously paid for 20 (at least 20) = 0 x \$ 18.00		\$	0.00
Independent claims after amendment 0 minus highest number previously paid for 3 (at least 3) = 0 x \$84.00		\$	0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)		\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)		\$	0.00
Terminal disclaimer enclosed, add \$ 110.00		\$	0.00
☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) ☐ Please enter the previously unentered , filed ☐ Submission attached		\$	0.00
	Subtotal	\$	0.00
If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status. Statement filed herewith		-\$	0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)		\$	0.00
Assignment Recording Fee (\$40.00)		\$	0.00
Other: Statement w/paper and computer-readable copies of Sequence Listing; copy of Notificebruary 27, 2002.	ication dated		0.00
TOTAL FI	EE ENCLOSED	\$	0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

BJS:eaw

NIXON & VANDERHYE P.C.

By Atty: B. J. Sadoff, Reg. No. 36,663

Signature:

0.00

1498-119 BJS



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box 90.1 United States Patent and Emissionark Officer Washington, D.C., 20233

Nixon & Vanderhye 8th Floor 1100 North Glebe Road Arlington, VA 22201-4714

CONFIRMATION NO. 3738
371 FORMALITIES LETTER

OC00000007492012

Date Mailed: 02/27/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Assignee Statement
- Claims
- · Copy of IPE Report
- Copy of references cited in ISR
- · Copy of the International Application
- · Copy of the International Search Report
- Drawings
- Initial Application Filing Fees
- · Oath or Declaration
- Oath or Declaration
- Original Specification
- · Preliminary Amendments
- · Request for Immediate Examination

DOCKETED

CLT/MATTER#_14	<u> 98-119</u>
MAIL DATE 2/27/2	
DUE DATE CON	27, 2002
FINAL DEADLINES	of 27, 2002
DOCKETED BY ME	
oddiana o. ma	1-10-

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (wher 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items MUST b ished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
 - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

FRANCINE YOUNG

Telephone: (703) 305-3662

PART 1 - ATTORNEY/APPLICANT COPY

· · · · · · · · · · · · · · · · · · ·			
U.S APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.	
09/763 824	PCT/GB99/03538	1498-119	

FORM PCT/DO/EO/905 (371 Formalities Notice)